Innorna, a clinical-stage biotech firm, has been nominated for the prestigious 2026 Prix Galien USA Best Startup award, highlighting its innovative RNA medicine platform and clinical projects.

HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- Innorna, a clinical-stage biotech company advancing RNA medicines, today announced that it has been nominated for the 2026 Prix Galien USA Best Startup Award. Innorna was shortlisted in the Best...

Biotech firm Innorna recognized for innovation in RNA drug development, nominated for 'Best Startup' at 2026 Prix Galien USA awards.

Innorna, a clinical-stage biotech company, has received a nomination for the 2026 Prix Galien USA Best Startup Award, recognizing their innovative RNA-based therapies.

HONG KONG SAR, China, SHENZHEN, China y CAMBRIDGE, Mass., 13 de agosto de 2026 /PRNewswire/ -- Innorna, una empresa de biotecnología en fase clínica que desarrolla medicamentos basados en ARN, anunció hoy que ha sido nominada para el premio 2026 Prix Galien USA Best Startup Award. Innorna...

Innorna, a biotech innovator specializing in RNA medicines, has garnered a nomination for the 2026 Prix Galien USA Best Startup Award, reflecting its significant advancements in therapeutics.

Innorna, a biotech firm advancing RNA medicines, has been nominated for the prestigious 2026 Prix Galien USA Best Startup Award, acknowledging its innovative therapeutic pipeline.

HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- Innorna, a clinical-stage biotech company advancing RNA medicines, today announced that it has been nominated for the 2026 Prix Galien USA Best Startup Award. Innorna was shortlisted in the Best...

Innorna Co., a Chinese developer of messenger RNA drugs backed by buyout firm CDH Investments, is planning an initial public offering in Hong Kong, according to people familiar with the matter.

Innorna, a Chinese biotech largely based in Shenzhen, won clearance from the FDA to begin a Phase 1 study of an mRNA therapy for refractory gout, the company told Endpoints News.

Innorna, a Chinese biotech largely based in Shenzhen, won clearance from the FDA to begin a Phase 1 study of an mRNA therapy for refractory gout, the company told Endpoints News.

Innorna has achieved a significant milestone with FDA approval for their mRNA-based therapy IN026, targeting refractory gout in patients. This innovation aims to transform treatment options for chronic metabolic diseases.

Innorna announced FDA's approval of IND for IN026, paving the way for innovative mRNA therapies targeting chronic metabolic diseases, including refractory gout.

Innorna has announced FDA clearance for IN026, an mRNA therapy targeting refractory gout, marking a significant advancement in chronic disease management.

Innorna has announced FDA clearance for IN026, an mRNA-based treatment targeting refractory gout, set to revolutionize chronic disease therapy.

Innorna has received FDA IND clearance for IN026, an innovative mRNA-based therapy aimed at treating refractory gout, potentially revolutionizing treatment options for patients.

IN026 est une thérapie ARNm potentielle de premier ordre pour la goutte réfractaire, marquant l'émergence d'une nouvelle catégorie de médicaments ARNm rendus possibles par la plateforme propriétaire ARNm-LNP d'Innorna. HONG KONG RAS, Chine et SHENZHEN, Chine et CAMBRIDGE, Massachusetts,...

IN026 ist eine potenzielle, in ihrer Klasse einzigartige mRNA-Therapie für refraktäre Gicht und markiert den Beginn einer neuen Kategorie von mRNA-Arzneimitteln, die durch die firmeneigene mRNA-LNP-Plattform von Innorna ermöglicht wird. SONDERVERWALTUNGSZONE HONGKONG, China und SHENZHEN,...

BOSTON & HONG KONG–(BUSINESS WIRE)–#GeneTherapy—Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual …